Study | Yamamoto | Motloch | Dhedin | Ben-Dor | Behan | Linke | Covello | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MA | GA | MAC | GA | MAC | GA | MAC | GA | MAC | GA | MAC | GA | MAC | GA | |
n | 130 | 44 | 41 | 33 | 34 | 91 | 42 | 27 | 9 | 3 | 547 | 449 | 42 | 27 |
Logistic EuroScore | 22.0* | 26.6* | NA | NA | 23.6 | 24 | 40.1* | 28.1* | 21.8 | 22.9 | ** | ** | 27.3 | 22.9 |
STS score (mortality) | 11.2 | 14.3 | 20.8 | 16.5 | 9.2* | 14* | NA | NA | NA | NA | NA | NA | NA | NA |
Prior CVA/TIA | 10.1% | 11.1% | 14.6% | 24.2% | 12% | 11% | 30%* | 9.1%* | 11% | 33% | NA | NA | 19% | 15% |
CAD | 10.1% | 11.1% | 43.9% | 42.4% | 44% | 52% | 55.7% | 45.5% | NA | NA | ** | ** | 57% | 44% |
Renal dysfunction (CrCl >60 ml/minute) | 68.5% | 63.6% | NA | NA | 56% | 44% | 37.1% | 50% | 11% | 0% | NA | NA | NA | NA |
Age | 83.7 | 84.7 | 82.6 | 83.4 | 83.5 | 83 | 84.1 | 83.7 | 80 | 83 | ** | ** | 79.5 | 77.6 |
Females | 60.5% | 53.3% | 65.9% | 45.5% | 47% | 50% | 58.5% | 63.6% | 33% | 33% | ** | ** | NA | NA |
Diabetes | 25.6% | 13.3% | 29.3% | 27.3% | 23% | 19% | 30% | 31.8% | NA | NA | ** | ** | 33% | 30% |
Hypertension | 81.4% | 73.3% | 82.5% | 75.8% | 74% | 64% | 90% | 95.5% | NA | NA | NA | NA | NA | NA |
COPD | 23.3% | 24.4% | 9.8% | 12.1% | 15% | 30% | 14.3% | 9.1% | 33% | 33% | NA | NA | 69% | 37% |
EF | 50.4%* | 45.1%* | 53.6% | 54.8% | 57% | 50% | 52.7% | 55.2% | NA | NA | NA | NA | NA | NA |
AVA (cm2) | 0.67 | 0.72 | 0.6 | 0.6 | 0.42 | 0.38 | 0.63 | 0.65 | NA | NA | NA | NA | NA | NA |